Literature DB >> 20525888

Combined genotypic and phenotypic killer cell Ig-like receptor analyses reveal KIR2DL3 alleles displaying unexpected monoclonal antibody reactivity: identification of the amino acid residues critical for staining.

Michela Falco1, Elisa Romeo, Stefania Marcenaro, Stefania Martini, Massimo Vitale, Cristina Bottino, Maria Cristina Mingari, Lorenzo Moretta, Alessandro Moretta, Daniela Pende.   

Abstract

In humans, recent clinical and experimental data from hematopoietic stem cell transplantation revealed that donor-derived alloreactive NK cells exert a beneficial graft versus leukemia effect. The existence of donor-derived alloreactive NK cells can be predicted on the basis of donor killer cell Ig-like receptor (KIR) gene profile and HLA class I typing of both donor and recipient. Moreover, the size of the alloreactive NK cell population can be directly assessed by the combined use of anti-KIR-specific mAb. In this study, in an attempt to improve the definition of alloreactive NK cell subsets, we assessed the KIR genotype and phenotype in a cohort of 44 donors. This approach allowed the identification of two different KIR2DL3 alleles (KIR2DL3*005 and the novel allele KIR2DL3*015) that did not react with the anti-KIR2DL3-specific ECM41 mAb. In contrast, both alleles were recognized at the cell surface by several mAb reacting with KIR2DL2/L3/S2. Notably, KIR2DL3*005 was also stained by the anti-KIR2DL1/S1-specific EB6B and 11PB6 mAb. Functional analysis revealed that, despite its particular mAb reactivity, the specificity of KIR2DL3*005 for HLA-C molecules did not differ from that of other KIR2DL2/L3 alleles. Finally, site-directed mutagenesis demonstrated that glutamine at position 35 is required for ECM41 staining, whereas glutamic acid 35 and arginine 50 are relevant for staining with EB6B or 11PB6 mAb. Our present data represent a substantial progress in the characterization of the NK cell repertoire and an improved phenotypic/functional definition of given KIR(+) subsets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20525888     DOI: 10.4049/jimmunol.0903632

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.

Authors:  K Czaja; A-S Borer; L Schmied; G Terszowski; M Stern; A Gonzalez
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

2.  Influence of KIR gene copy number on natural killer cell education.

Authors:  Vivien Béziat; James A Traherne; Lisa L Liu; Jyothi Jayaraman; Monika Enqvist; Stella Larsson; John Trowsdale; Karl-Johan Malmberg
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113

3.  Increased frequency and function of KIR2DL1-3⁺ NK cells in primary HIV-1 infection are determined by HLA-C group haplotypes.

Authors:  Christian Körner; Mitchell E Granoff; Molly A Amero; Michael N Sirignano; Sagar A Vaidya; Stephanie Jost; Todd M Allen; Eric S Rosenberg; Marcus Altfeld
Journal:  Eur J Immunol       Date:  2014-08-12       Impact factor: 5.532

4.  NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs.

Authors:  Vivien Béziat; Lisa L Liu; Jenny-Ann Malmberg; Martin A Ivarsson; Ebba Sohlberg; Andreas T Björklund; Christelle Retière; Eva Sverremark-Ekström; James Traherne; Per Ljungman; Marie Schaffer; David A Price; John Trowsdale; Jakob Michaëlsson; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

5.  Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.

Authors:  William R Frazier; Noriko Steiner; Lihua Hou; Sivanesan Dakshanamurthy; Carolyn Katovich Hurley
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

6.  Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.

Authors:  María V Martínez-Sánchez; Adela Periago; Isabel Legaz; Lourdes Gimeno; Anna Mrowiec; Natividad R Montes-Barqueros; José A Campillo; José M Bolarin; María V Bernardo; María R López-Álvarez; Consuelo González; María C García-Garay; Manuel Muro; Valentin Cabañas-Perianes; Jose L Fuster; Ana M García-Alonso; José M Moraleda; María R Álvarez-Lopez; Alfredo Minguela
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

7.  Killer Immunoglobulin-Like Receptor Allele Determination Using Next-Generation Sequencing Technology.

Authors:  Bercelin Maniangou; Nolwenn Legrand; Mehdi Alizadeh; Ulysse Guyet; Catherine Willem; Gaëlle David; Eric Charpentier; Alexandre Walencik; Christelle Retière; Katia Gagne
Journal:  Front Immunol       Date:  2017-05-19       Impact factor: 7.561

8.  High-Resolution Genetic and Phenotypic Analysis of KIR2DL1 Alleles and Their Association with Pre-Eclampsia.

Authors:  Oisín Huhn; Olympe Chazara; Martin A Ivarsson; Christelle Retière; Timothy C Venkatesan; Paul J Norman; Hugo G Hilton; Jyothi Jayaraman; James A Traherne; John Trowsdale; Mitsutero Ito; Christiane Kling; Peter Parham; Hormas Ghadially; Ashley Moffett; Andrew M Sharkey; Francesco Colucci
Journal:  J Immunol       Date:  2018-09-24       Impact factor: 5.422

9.  Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation.

Authors:  Vivien Béziat; James Traherne; Jenny-Ann Malmberg; Martin A Ivarsson; Niklas K Björkström; Christelle Retière; Hans-Gustaf Ljunggren; Jakob Michaëlsson; John Trowsdale; Karl-Johan Malmberg
Journal:  Eur J Immunol       Date:  2014-05-07       Impact factor: 5.532

10.  The Size of Activating and Inhibitory Killer Ig-like Receptor Nanoclusters Is Controlled by the Transmembrane Sequence and Affects Signaling.

Authors:  Anna Oszmiana; David J Williamson; Shaun-Paul Cordoba; David J Morgan; Philippa R Kennedy; Kevin Stacey; Daniel M Davis
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.